Hepatoprotective Effects of Biochanin A Against Acetaminophen-induced Liver Toxicity in Mice

Maryam Shirani 1, Nazanin Reisi 1,2, Hadi Kalantar 1, Laya Sadat Khorsandi 3 and Mohammad Javad Khodayar 1,4,*

1Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2Department of Toxicology, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding author: Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: khodayar-mj@ajums.ac.ir

Received 2023 January 03; Revised 2023 March 11; Accepted 2023 April 08.

Abstract

Background: Acetaminophen (APAP), a common analgesic agent, is hepatotoxic in overdose. N-acetylcysteine (NAC), as an APAP antidote, shows anaphylactic reactions and has low efficacy in APAP poisoning in high doses.

Objectives: This study was designed to examine the hepatoprotective effect of biochanin A (BA) in a mice model of acetaminophen-induced hepatotoxicity.

Methods: To evaluate APAP-induced oxidative stress, the liver tissue level of malondialdehyde (MDA) and glutathione (GSH) and the activities of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), catalase, and superoxide dismutase (SOD) were measured. Histological analysis was performed.

Results: APAP-induced hepatotoxicity was manifested by inflammation, acinar hepatic necrosis, and fatty degeneration, as well as an increase in the levels of ALP, ALT, AST, MDA, and a decrease in the SOD, catalase (CAT), and GSH. Pre-treatment with BA at low doses (10 and 20 mg/kg) reduced ALT, AST, and MDA levels and raised the SOD, GSH, and CAT levels. Moreover, it normalized the structure of liver tissue.

Conclusions: The results of this study indicated that BA protected the liver from APAP-induced injury. Protection may be due to the inhibition of oxidative stress, which reduces liver inflammation.

Keywords: Acetaminophen, Oxidative Stress, Biochanin A, Hepatoprotective

1. Background

Acetaminophen (APAP) is one of the most common over-the-counter antipyretic/analgesic medications for fever or pain (1, 2). Although acute overdose or cumulative chronic use of APAP is well tolerated at typical therapeutic doses, it can also lead to severe hepatic necrosis and acute liver failure (3-5).

At therapeutic levels in body cells, APAP is converted by cytochrome P450 (CYP450) isozymes (CYP2E1, CYP3A4, and CYP1A2) to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is subsequently detoxified by hepatic glutathione (GSH) reserves. It binds to various mitochondrial macromolecules (DNA, lipids, and cysteine groups in proteins), leading to mitochondrial dysfunction and the production of reactive oxygen species (ROS), especially superoxide anions. Finally, impaired mitochondrial respiration and oxidation of lipids and other molecules, along with the death of hepatocytes and activated inflammatory cells, lead to hepatocyte necrosis and liver damage (7-10).

The only treatment for APAP-induced hepatotoxicity is N-acetylcysteine (NAC). This substance can prevent liver damage by restoring GSH. However, because of its adverse effects and narrow therapeutic window, it is vital to find new agents superior to NAC in terms of effectiveness and safety (11). In recent years, there has been a growing interest in discovering and developing harmless and efficient natural products against APAP-induced hepatotoxicity. Antioxidant phytochemicals can delay or inhibit oxidative chain reactions (14, 15).

Flavonoids are phenolic compounds that exert their antioxidant activity by modulating different signaling pathways, including the production of reactive oxygen species.
pathways (16, 17). Biochanin A (BA) is an O-methylated flavonoid in various plants, such as red clover, alfalfa sprouts, and peanuts (18, 19). A broad spectrum of pharmacological properties has been reported for BA, including anti-inflammatory, antioxidative, antineoplastic, carcinogenic, and hypolipidemic effects (18, 20).

2. Objectives

The present study aimed to assess the effects of BA on acetaminophen-induced liver toxicity in mice.

3. Methods

3.1. Chemicals

BA, APAP, and DTNB were prepared from Sigma Chemical Co. (USA). Thiobarbituric acid (TBA) was prepared by Merck Company. The rest of the chemicals used in this study were purchased from local firms in Iran and were of analytical grade.

3.2. Animal Experiments

Adult male Naval Medical Research Institute (NMRI) mice (weighing 25 - 30 g) were used for this study. The study was approved by the Animal Research Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (ethical approval ID: IR.AJUMS.ABHC.REC.1397.066). APAP and BA were dissolved in warm saline and 1% DMSO solutions, respectively. The animals were randomly divided into six groups (seven animals in each group): Group 1 received normal saline (NA, gavage) and was used as control; group 2 was exposed to BA alone (40 mg/kg, oral); group 3 received APAP alone (300 mg/kg); and groups 4, 5, and 6 were co-treated by APAP and BA at doses of 10, 20, and 40 mg/kg, respectively. BA was administered before and 2 and 4 hours after APAP (11, 18).

3.3. Biochemical Blood Tests

Seven hours after the end of treatment, the animals were sacrificed after a night of fasting. For biochemical tests, the blood was immediately collected in the anticoagulant tubes and centrifuged for 15 min at 2000 g to obtain serum. Serum samples were used to investigate liver biomarkers, such as alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP).

3.4. Liver Tissue Lipid Peroxidation Assay

The lipid peroxidation rate in the liver was calculated by forming TBA reactive materials. The liver tissue was added to TBA and then centrifuged for 15 min. After adding TBA, the samples were placed in the water bath. Finally, the absorbance of the samples was read at 532 nm, and the lipid peroxidation rate was reported as nmol/mg protein (18).

3.5. Determination of Liver Tissue Antioxidants Assay

Reduced GSH content was measured in the liver using DTNB as an indicator. Briefly, the liver tissue specimens were homogenized in phosphate buffer. Tissue homogenates were mixed with TCA and centrifuged. Supernatant fractions were mixed with phosphate buffer and DTNB solution. The produced yellow color was read by a spectrophotometer at 412 nm. The GSH content was calculated according to a standard curve and was expressed as nmol/mg protein (18). Superoxide dismutase (SOD) and catalase (CAT) activities were measured according to the manufacturer’s protocol of the ZellBio kit (ZellBio GmbH, Germany). The results were reported as U/mg protein.

3.6. Histopathological Evaluation

After fixing the liver tissue in formalin solution, dehydrating it in graded alcohol concentrations, embedding it in paraffin, and preparing 4 - 6 micrometers sections, the samples were stained with hematoxylin and eosin (H&E). Histological changes, such as fat deposition in liver cells, congestion of red blood cells (RBCs), infiltration of inflammatory cells, and central lobular necrosis, were examined in microscopic slides. Histological characteristics were graded into four categories normal (0), weak (1), moderate (2), or severe (3), and the averages were considered (11).

3.7. Statistical Analysis

Descriptive results are provided as mean ± SEM. One-way analysis of variance (ANOVA) and Tukey’s post hoc analysis were applied to compare the groups. P-value < 0.05 was considered statistically significant (in each group, n = 7, * in comparison with the control group and # in comparison with the APAP group).

4. Results

4.1. Biochemical Blood Tests

As shown in Figure 1, APAP significantly increased ALP, AST, and ALT levels in the toxic group compared to the NA group. Pre-treatment by BA caused a marked decrease in the levels of ALP, AST, and ALT that were raised by APAP. Moreover, the most significant change was observed at the
dose of 20 mg/kg (P < 0.05). In addition, the administration of BA alone (40 mg/kg) showed a toxic effect on the AST level compared to the control group.

4.2. Liver Tissue Lipid Peroxidation Assay

Gavage administration of APAP significantly raised the malondialdehyde (MDA) level compared to the control group (P = 0.01). However, BA (10 and 20 mg/kg) caused a significant reduction in MDA level in comparison with the APAP group (P = 0.01 and P = 0.001, respectively) (Figure 2).

4.3. Determination of Reduced Glutathione Level

Figure 3 displays the GSH concentrations in the livers of various animal groups. Compared to the control group, GSH levels were significantly lower after APAP treatment (P < 0.05). In comparison with the control animals, GSH levels were lower after receiving 40 mg/kg of BA (P < 0.05). The APAP groups (20 mg/kg) treated with BA and the APAP group were significantly different in terms of the GSH levels.

4.4. Antioxidant Enzymes Assessments

We observed a statistically significant difference in the catalase enzyme activity between the APAP-treated and control groups (P < 0.001). The APAP group treated with BA (20 mg/kg) showed a significant increase in catalase enzyme activity compared to the control group (P < 0.001). A marked reduction was found in the hepatic content of SOD in the animals treated with APAP alone, APAP + BA, and BA alone (40 mg/kg) (P < 0.01, P < 0.01, and P < 0.05, respectively). BA at the dose of 20 mg/kg reduced the hepatic content of SOD in mice treated with a combination of BA and APAP compared to animals treated only with APAP (Figure 4).

4.5. Histopathological Evaluation

Using H&E histological examination, the presence of APAP-induced hepatotoxicity was approved. The H&E staining of liver tissue sampled from mice showed inflammation, acinar necrosis, and hepatocyte necrosis. Moreover, during the histological analysis, fat deposits were observed. In contrast, BA at 10 and 20 mg/kg doses significantly restored hepatocellular damage brought on by APAP (Figure 5 and Table 1).

5. Discussion

The liver is recognized as the vital organ that controls the metabolism of lipids, glucose, and energy (21). The liver tissue of APAP-treated animals underwent a histological analysis, which demonstrated histopathological alterations linked to hepatic toxicity. Oxidative stress, APAP-induced lipid peroxidation, and the consequent disturbance of liver function and structure may be attributed to the damage to liver tissue (22). By pretreating mice with BA (10 and 20 mg/kg), the histological damages, such as necrosis, inflammatory RBC congestion, and fat deposit, were also noticeably reduced. One potential mechanism is that BA scavenges ROS in order to suppress them (20).

The BA-treated group showed substantial histological alterations. Similar findings have already been published (19, 23). The ALP, ALT, and AST activities are regarded as sensitive markers of liver damage (24). Numerous investigations have revealed increased liver-associated enzyme activity in the plasma of animals exposed to APAP (25, 26). According to our findings, which were in line with those of earlier studies, serum levels of ALP, ALT, and AST were elevated in animals exposed to APAP. This may be primarily because of cellular leakage into the blood as a result of the loss of functional integrity of the hepatic membrane, nuclear DNA damage, and subsequent cell death (27).

Comparing the APAP-induced animal with the control group, the oral administration of BA, especially at a dose of 20 mg/kg, dramatically reversed these changes, demonstrating cellular integrity preservation and membrane protective effects, which finally prevent the leakage of cytoplasmic enzymes and components into the serum and cell death (18, 28). According to earlier studies, APAP has a negative effect on the hepatic tissue. Our findings that APAP 300 mg/kg increased the development of MDA in the liver support those findings (29, 30). In this regard, we demonstrated that treatment with BA (10 and 20 mg/kg) significantly reduced MDA levels in mice treated with APAP, which could be related to the ability of BA to scavenge free radicals and inhibit inflammation and oxidative stress (31, 32).

Enzymatic antioxidants SOD and CAT neutralize free radicals generated during oxidative stress. SOD catalyzes the conversion of H$_2$O$_2$ into water and oxygen, which is then deactivated by CAT (33). According to the available data, the livers of mice treated with APAP had considerably reduced levels of oxidative stress enzymes SOD and CAT because of increased superoxide radical anions generation and insufficient NADPH reserves (34, 35). Numerous animal studies have indicated that BA can prevent oxidative liver damage, which may result from effective free radical scavenging abilities and the potential to boost CAT and SOD activity (18, 19).

Our results showed that administering BA at a dose of 20 mg/kg significantly increased SOD and CAT activities in APAP-exposed animals, consistent with earlier find-
**Figure 1.** Effects of biochanin A (BA) on aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) levels.
Table 1. Effects of Biochanin A on Histopathological Changes in Liver Tissues

<table>
<thead>
<tr>
<th>Groups</th>
<th>Histological Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RBCs Congestion</td>
</tr>
<tr>
<td>Control</td>
<td>0.13 ± 0.00</td>
</tr>
<tr>
<td>APAP</td>
<td>2.26 ± 0.33 ***</td>
</tr>
<tr>
<td>APAP + BA10</td>
<td>0.52 ± 0.08 **##</td>
</tr>
<tr>
<td>APAP + BA20</td>
<td>0.61 ± 0.24 **##</td>
</tr>
<tr>
<td>APAP + BA40</td>
<td>2.42 ± 0.36 ***</td>
</tr>
<tr>
<td>BA40</td>
<td>1.92 ± 0.26 ***</td>
</tr>
</tbody>
</table>

Abbreviations: RBC, red blood cells; APAP, acetaminophen; BA10, biochanin A 10 mg/kg; BA20, biochanin A 20 mg/kg; BA40, biochanin A 40 mg/kg

Values are expressed as mean ± SD.

Figure 2. Effects of biochanin A (BA) on the liver malondialdehyde (MDA) levels

Figure 3. Effects of biochanin A (BA) on liver glutathione (GSH) levels

5.1. Conclusions

In conclusion, our results indicated that BA at an optimal dose (low dose) could be protective against APAP-induced hepatic injury in mice. Protection may be due to its ability to reverse the imbalance between free radical production and degradation by antioxidant systems with an increased accumulation of ROS in the liver tissue, subsequently improving liver inflammation.

Footnotes

Authors’ Contribution: M. Sh. and H. K. designed the study and interpreted the data. M. Sh., N. R., and M. J. Kh. collected the data, performed experimental analysis, and interpreted the data. M. J. Kh. and L. Kh. drafted the manuscript. All the authors read and approved the final version of the manuscript.

Figure 4. Effects of biochanin A (BA) on catalase (CAT) and superoxide dismutase (SOD).

Figure 5. Effect of biochanin A (BA) on the histopathological lesions of acetaminophen (APAP)-induced liver injury. The beneficial effects of BA are shown in the figure. Arrows: A, accumulation of blood cells (RBCs); I, Inflammation; N, Necrosis; F, Fat deposit; Magnification: ×100.
Conflict of Interests: The authors have no conflict of interest.

Ethical Approval: The ethical approval code is IR.AJUMS.ABHC.REC.1397.066.

Funding/Support: The grant number is B-97092.

References


